Multi-Endogenous Nanoformulation for Endocannabinoid and Hormonal Modulation of Key Signaling Pathways in Resistant...

Area of Science:

• Biomedical Engineering
• Cardiovascular Research
• Nanomedicine

Background:

• Resistant hypertension presents a significant clinical challenge despite advances in synthetic therapies.
• Multifactorial resistance mechanisms involve key signaling pathways such as heat shock protein 70 (Hsp70), Wilms tumor 1 (WT1), angiotensin II type 1 receptor (AT1), and inducible nitric oxide synthase (iNOS).

Purpose of the Study:

• To explore the potential of endogenous bioactive compounds delivered via controlled nanosystems for treating resistant hypertension.
• To investigate the efficacy of co-delivering multiple agents to enhance bioavailability, stability, and therapeutic precision.

Main Methods:

• Utilizing nanoformulations for controlled and sustained release of endogenous bioactive compounds.
• Simultaneous modulation of Hsp70, WT1, AT1, and iNOS signaling pathways.

Main Results:

• Nanoformulations enable co-delivery of multiple agents, improving bioavailability and stability.
• This approach facilitates effective modulation of hypertension pathophysiology, including inflammation, oxidative stress, and vascular dysfunction.

Conclusions:

• Nanoformulations offer a promising strategy for treating resistant hypertension and related cardiovascular disorders.
• Further research is needed to optimize these delivery systems and evaluate their efficacy in clinical models.